President Trump's Trade Policies and China's Biotech Boom Challenge Europe's Pharma Industry
Europe's pharmaceutical industry, once a global leader, is facing significant challenges due to President Trump's aggressive trade and drug-pricing policies and China's rapid advancements in biotech. Historically, Europe was a major hub for research and development, but its share has decreased significantly, with the U.S. now leading in R&D investment. Trump's policies, including tariffs and most-favored-nation drug pricing, are pressuring European companies to reconsider their investment strategies. Meanwhile, China is emerging as a key player in biotech innovation, attracting global pharmaceutical companies. This shift is causing European companies to delay drug launches and reconsider their pricing strategies, potentially leading to a reallocation of investments towards the U.S. 
